2022 Clinical Pharmacology Process Chemistry Trials 
Metabolite Tales Blog
JULY 5, 2023
Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed. Synthetic macrocycles in oncology Pactritinib is a multi-kinase JAK2/FLT3 inhibitor used for the treatment of primary and secondary myelofibrosis, approved by the FDA in 2022. Journal of Medicinal Chemistry, 66 (8), 5377-5396.
Metabolite Tales Blog
JULY 5, 2023
Still, of the 34 macrocycles currently in clinical trials, only 18% are de novo designed. Synthetic macrocycles in oncology Pactritinib is a multi-kinase inhibitor used for the treatment of primary and secondary myelofibrosis and was approved by the FDA in 2022. Journal of Medicinal Chemistry, 66 (8), 5377-5396.
Expert insights. Personalized for you.
52 
Let's personalize your content